Loading stock data…
$40.40-1.61 (-3.83%)
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.
Supernus Pharmaceuticals, Inc. in the Healthcare sector is trading at $40.44 with a market capitalization of $2.5B. Wall Street consensus targets $61.75 (4 analysts), implying a +52.7% move over the next 12 months. The stock is currently near its 52-week low of $40.41, remaining 15.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $219.06M↑ | $207.71M↓ | $211.57M↑ | $192.10M↑ | $165.45M |
| Gross Profit | $185.39M↑ | $184.31M↓ | $188.56M↑ | $173.14M↑ | $148.63M |
| Operating Income | -$3.04M↑ | -$5.94M↓ | $13.82M↑ | -$60.23M↓ | $12.14M |
| Net Income | -$58.37M↓ | -$2.29M↑ | -$4.11M↑ | -$45.12M↓ | $22.50M |
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated fo...